Australia: Antitrust authority approves new regulations to increase pharma transparency
The Australian Competition and Consumer Commission has given Australia’s pharmaceutical companies a timeline of two years to improve transparency in regards to the companies’ payments and sponsorships to healthcare professionals. While originally sought for a five year acceptance, Medicines Australia’s most recent Code of Conduct has been approved for two years; the new regulations are aimed at ensuring the makers of prescription drugs disclose the doctors and consumer groups they pay.
Featured News
NBA Teams Up With US Regulator on Prediction Markets
Oct 27, 2026 by
CPI
Intesa Wins ECB Approval for $36 Billion Monte dei Paschi Takeover
Oct 27, 2026 by
CPI
PayPal, Revolut Weigh In as UK Targets Apple’s Tap-to-Pay Rules
Oct 27, 2026 by
CPI
Heineken Ordered to Pay $124 Million in Greek Antitrust Case
Oct 27, 2026 by
CPI
FTC Raises Antitrust Concerns Over Cintas’ $5.5 Billion Deal
Oct 27, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI